Spero therapeutics to report second quarter 2024 financial results and provide business update on monday, august 5, 2024

Cambridge, mass., july 29, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that management will host a conference call and live audio webcast on monday august 5th, 2024 at 4:30 p.m. et to report financial results for second quarter 2024 and provide an update on its business and pipeline.
SPRO Ratings Summary
SPRO Quant Ranking